ClinicalTrials.gg
CompletedNCT01227278Updated Oct 5, 2016Results posted

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Placebo and Benralizumab 100 mg in Pulmonary Disease, Chronic Obstructive, sponsored by MedImmune LLC. Completed at 31 sites in 7 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-10-05.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
421
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
66th of 194
421 · median 137
Started
2010
with 24 others
Phase 2
54 of 284
1 open now
Registered
81st of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 66th largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2010, is one of 54 in phase 2, and was the 81st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.

Read the detailed description

To evaluate the effect of multiple subcutaneous (SC) doses of benralizumab (MEDI 563) on the rate of moderate-to-severe annualized incidence rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with moderate-to-severe COPD who exhibit eosinophilia (greater than or equal to [>=] 3.0 percent [%] sputum eosinophilia in the previous 12 months or at Screening) in sputum compared to placebo.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Benralizumab
  • MEDI-563
  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 40-85 years at the time of Screening
  • Written obtained from the subject prior to performing any protocol related procedures
  • Documented history of 1 or more Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of (AECOPD)
  • Current smoker or ex-smoker with a tobacco history of greater than or equal to (>=) 10 pack-years
  • Adequate from screening through end of trial
  • Able to read and write.

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the product or interpretation of subject safety or study results
  • Pregnant, breastfeeding, or lactating women
  • Known history of allergy or reaction to any component of the investigational product formulation
  • History of anaphylaxis to any other biologic therapy
  • Donation or transfusion of blood, plasma or within the past 3 months prior to Screening
  • Other significant pulmonary disease which in the opinion of the investigator or medical monitor, might compromise the interpretation of the study
  • Fever greater than (>) 37.0 degree Centigrade (98.6 degree Fahrenheit) at Screening
  • Receipt of any novel investigational medicinal product within 3 months before the first dose of investigational product in this study and through the end of the study
  • Seropositive for hepatitis A, surface antigen, , or 1or 2 (HIV-1 or HIV 2)
  • History of alcohol or drug abuse within the past year that required treatment that the investigator felt or medical monitor felt would compromise the study data interpretation
  • Past or current within the past 5 years except adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than 1 year prior to Screening
  • Subjects participating in, or scheduled for, an intensive rehabilitation program (subjects who are in the maintenance phase of a rehabilitation program are eligible to take part)
  • Current diagnosis of asthma according to Global Initiative for Asthma guidelines
  • Previous treatment with MEDI-563.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
421 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

    Other: Placebo

  • Experimental
    Benralizumab 100 mg

    Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

    Biological: Benralizumab 100 mg

Interventions

  • OtherPlacebo

    Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

  • Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

    Also known as: MEDI-563

06

What researchers measure

Primary outcomes

  1. Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

    An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days. Annualized Incidence Rate of Moderate or Severe AECOPD was assessed based on AECOPD data up to Day 393 (Rate = total number of moderate or severe AECOPD in each group/total person-year follow-up in each group). The severity of an exacerbation of COPD is defined as: a) Mild exacerbations, which require treatment with an increase in usual therapy, example (eg), increase use of short acting bronchodilators, b) Moderate exacerbations which require treatment with systemic corticosteroids, and or antibiotics and c) Severe exacerbations which require hospitalization.

    Time frame: Day 1 up to 393

Secondary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Day 561 that were absent before treatment or that worsened relative to pre-treatment state. TEAEs reported below included both SAEs and non-serious AEs.

    Time frame: Day 1 up to 561

  2. Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

    An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.

    Time frame: Day 1 up to 393

  3. Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

    An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.

    Time frame: Day 1 up to 393

  4. Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

    An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days. Annualized Incidence Rate of hospitalization due to AECOPD was calculated as Rate = total number of hospitalizations/ total person years.

    Time frame: Day 1 up to 393

  5. Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393

    The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100. The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.

    Time frame: Baseline, Day 393

  6. Percentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score

    SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100. The total score and domain score were derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status. Percentage of participants with 4-point, 8-point and 12-point change from baseline in SGRQ-C total score were observed.

    Time frame: Day 393

  7. Change From Baseline in Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) Domain Scores at Day 393

    The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items). Participants rated their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment). Individual items were equally weighted, and domain scores were calculated as the mean of all items within each domain; domain score range: 1 (maximum impairment) to 7 (no impairment).

    Time frame: Baseline, Day 393

  8. Percentage of Participants With a 0.5-Point Improvement in Chronic Respiratory Questionnaire Self-administered Standardized Format (CRQ-SAS) Domain Scores at Day 393

    The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items). Participants rated their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment). Individual items were equally weighted, and domain scores were calculated as the mean of all items within each domain; domain score range: 1 (maximum impairment) to 7 (no impairment). Participants with 0.5 point improvement from baseline in the domain scores were observed.

    Time frame: Day 393

  9. Change From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Scores at Day 393

    The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test. The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe ). BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).

    Time frame: Baseline, Day 393

07

Results

Posted Oct 5, 2016

Participant flow

A total of 421 participants were screened and 101 participants were randomized into the study.

Participant flow — Overall Study
MilestonePlaceboBenralizumab 100 mg
Started5051
Completed4543
Not completed58
Withdrew: Withdrawal by subject44
Withdrew: Death02
Withdrew: Other12

Outcome measures

PrimaryAnnualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days. Annualized Incidence Rate of Moderate or Severe AECOPD was assessed based on AECOPD data up to Day 393 (Rate = total number of moderate or severe AECOPD in each group/total person-year follow-up in each group). The severity of an exacerbation of COPD is defined as: a) Mild exacerbations, which require treatment with an increase in usual therapy, example (eg), increase use of short acting bronchodilators, b) Moderate exacerbations which require treatment with systemic corticosteroids, and or antibiotics and c) Severe exacerbations which require hospitalization.

Time frame:
Day 1 up to 393
Reported as:
Number · AECOPD events/person-year
Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
AECOPD events/person-yearPlaceboBenralizumab 100 mg
Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)0.92 (0.67 to 1.25)0.95 (0.68 to 1.29)
Statistical analysis
  • Placebo vs Benralizumab 100 mg · Van Elteren Test · p = 0.941 · Rate ratio: 1.03 · 95% CI 0.67 to 1.5895 percent (%) confidence interval (CI) for rate ratio was based on normal approximation assuming rate with Poisson distribution.
SecondaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Day 561 that were absent before treatment or that worsened relative to pre-treatment state. TEAEs reported below included both SAEs and non-serious AEs.

Time frame:
Day 1 up to 561
Reported as:
Number · participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
participantsPlaceboBenralizumab 100 mg
TEAEs4145
TESAEs914
SecondaryNumber of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.

Time frame:
Day 1 up to 393
Reported as:
Number · participants
Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
participantsPlaceboBenralizumab 100 mg
Number of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)52
SecondaryPercentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days.

Time frame:
Day 1 up to 393
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
percentage of participantsPlaceboBenralizumab 100 mg
Percentage of Participants Hospitalized Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)11.95.0
SecondaryAnnual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

An AECOPD is defined as worsening of two or more major symptoms or one major and one minor symptom for two or more consecutive days. Annualized Incidence Rate of hospitalization due to AECOPD was calculated as Rate = total number of hospitalizations/ total person years.

Time frame:
Day 1 up to 393
Reported as:
Number · hospitalizations/person-year
Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
hospitalizations/person-yearPlaceboBenralizumab 100 mg
Annual Incidence Rate of Hospitalization Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)0.11 (0.05 to 0.26)0.05 (0.01 to 0.18)
SecondaryChange From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393

The SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100. The total score and domain score are derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status.

Time frame:
Baseline, Day 393
Reported as:
Mean · units on scale
Change From Baseline in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total and Domain Scores at Day 393
units on scalePlaceboBenralizumab 100 mg
Baseline: Total Score (n=42, 40)48.04 ± 19.1451.75 ± 20.45
Change at Day 393: Total Score (n=42, 37)-4.43 ± 11.71-5.51 ± 16.64
Baseline: Symptoms (n=42, 40)64.59 ± 24.3867.18 ± 21.47
Change at Day 393: Symptoms (n=42, 37)-3.19 ± 17.44-9.02 ± 21.27
Baseline: Activity (n=42, 40)58.85 ± 23.2261.45 ± 25.53
Change at Day 393: Activity (n=42, 37)-5.65 ± 14.85-4.37 ± 24.89
Baseline: Impact (n=42, 40)35.94 ± 18.9540.69 ± 22.49
Change at Day 393: Impact (n=42, 37)-4.16 ± 14.62-4.95 ± 16.97
SecondaryPercentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score

SGRQ is a health related quality of life questionnaire consisting of 40 items in three domains: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). Each question's response has a unique empirically derived weight where lowest possible weight is zero and the highest is 100. The total score and domain score were derived from the relevant items and converted to a score of 0 to 100 with a higher score indicating poorer health status. Percentage of participants with 4-point, 8-point and 12-point change from baseline in SGRQ-C total score were observed.

Time frame:
Day 393
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in COPD-Specific Saint George's Respiratory Questionnaire (SGRQ-C) Total Score
percentage of participantsPlaceboBenralizumab 100 mg
Day 393, Total: 4-point change (n=42, 37)59.554.1
Day 393: 8-point change (n=42, 37)38.140.5
Day 393, Total: 12-point change (n=42, 37)21.424.3
SecondaryChange From Baseline in Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) Domain Scores at Day 393

The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items). Participants rated their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment). Individual items were equally weighted, and domain scores were calculated as the mean of all items within each domain; domain score range: 1 (maximum impairment) to 7 (no impairment).

Time frame:
Baseline, Day 393
Reported as:
Mean · units on scale
Change From Baseline in Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) Domain Scores at Day 393
units on scalePlaceboBenralizumab 100 mg
Baseline: Dyspnea (n=42, 40)4.97 ± 1.454.74 ± 1.32
Change at Day 393: Dyspnea (n=42, 37)-0.08 ± 1.290.09 ± 1.00
Baseline: Fatigue (n=42, 40)4.38 ± 1.263.96 ± 1.40
Change at Day 393: Fatigue (n=42, 37)0.11 ± 0.940.11 ± 1.15
Baseline: Emotional function (n=42, 40)4.84 ± 1.244.72 ± 1.17
Change at Day 393: Emotional function (n=42, 37)0.18 ± 0.980.08 ± 1.18
Baseline: Mastery (n=42, 40)4.89 ± 1.504.67 ± 1.40
Change at Day 393: Mastery (n=42, 37)0.24 ± 1.120.28 ± 1.24
SecondaryPercentage of Participants With a 0.5-Point Improvement in Chronic Respiratory Questionnaire Self-administered Standardized Format (CRQ-SAS) Domain Scores at Day 393

The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items). Participants rated their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment). Individual items were equally weighted, and domain scores were calculated as the mean of all items within each domain; domain score range: 1 (maximum impairment) to 7 (no impairment). Participants with 0.5 point improvement from baseline in the domain scores were observed.

Time frame:
Day 393
Reported as:
Number · percentage of participants
Percentage of Participants With a 0.5-Point Improvement in Chronic Respiratory Questionnaire Self-administered Standardized Format (CRQ-SAS) Domain Scores at Day 393
percentage of participantsPlaceboBenralizumab 100 mg
Day 393: Dyspnea (n=42, 37)28.632.4
Day 393: Fatigue (n=42, 37)35.735.1
Day 393: Emotional function (n=42, 37)35.727.0
Day 393: Mastery (n=42, 37)47.637.8
SecondaryChange From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Scores at Day 393

The BODE index is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the modified medical research council (MMRC) dyspnea scale and the 6-minute walk test. The MMRC dyspnea scale is a 5-point scale that measures the level of dyspnea (trouble breathing) experienced by participants where score range is 0 (none) to 4 (very severe ). BODE score is derived into a score range of 0 (healthy) to 10 (severe COPD).

Time frame:
Baseline, Day 393
Reported as:
Mean · units on scale
Change From Baseline in Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Scores at Day 393
units on scalePlaceboBenralizumab 100 mg
Baseline (n=40, 39)2.8 ± 2.02.9 ± 1.8
Change at Day 393 (n=37, 32)-0.1 ± 1.4-0.5 ± 1.4

Adverse events

Collected over Day 1 to 561. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—9/50 (18%)41/50 (82%)
Benralizumab 100 mg—14/51 (27.5%)44/51 (86.3%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPlaceboBenralizumab 100 mg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders6/506/51
ConstipationGastrointestinal disorders1/500/51
BronchitisInfections and infestations1/501/51
Lower respiratory tract infectionInfections and infestations1/500/51
Non-hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/500/51
PresyncopeNervous system disorders1/500/51
Alcohol withdrawal syndromePsychiatric disorders1/500/51
Cardiac failure congestiveCardiac disorders0/501/51
Myocardial infarctionCardiac disorders0/501/51
Small intestinal obstructionGastrointestinal disorders0/501/51
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlaceboBenralizumab 100 mg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders25/5026/51
NasopharyngitisInfections and infestations11/505/51
DyspnoeaRespiratory, thoracic and mediastinal disorders5/502/51
Upper respiratory tract infectionInfections and infestations1/505/51
Abdominal pain upperGastrointestinal disorders4/500/51
DiarrhoeaGastrointestinal disorders4/500/51
SinusitisInfections and infestations4/503/51
CoughRespiratory, thoracic and mediastinal disorders4/501/51
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/500/51
PharyngitisInfections and infestations1/504/51

Baseline characteristics

Intent-to-treat (ITT) population included all participants randomized into the study.

Age, Continuous
Age, Continuous(years)PlaceboBenralizumab 100 mgTotal
Mean64.6 ± 7.562.9 ± 8.263.7 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBenralizumab 100 mgTotal
Female211637
Male293564
08

Study locations

31 sites
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Marietta, Georgia, United States
  • Research Site
    Normal, Illinois, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Greenville, South Carolina, United States
  • Research Site
    Boerne, Texas, United States
  • Research Site
    Tyler, Texas, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Saskatoon, Saskatchewan, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Hellerup, Denmark
  • Research Site
    København NV, Denmark
  • Research Site
    Odense C, Denmark
  • Research Site
    Århus C, Denmark
  • Research Site
    Frankfurt, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Gdańsk, Poland
  • Research Site
    Kraków, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Łódź, Poland
  • Research Site
    Barcelona, Spain
  • Research Site
    Lérida, Spain
  • Research Site
    Málaga, Spain
  • Research Site
    Oviedo, Spain
  • Research Site
    Cambridge, United Kingdom
  • Research Site
    Edinburgh, United Kingdom
  • Research Site
    Leicester, United Kingdom
  • Research Site
    Manchester, United Kingdom
09

References and documents

Publications

  • Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019 Jan 18;20(1):14. doi: 10.1186/s12931-018-0968-8. PubMed 30658649 ↗
  • Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7. PubMed 25208464 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2010
First posted
Oct 25, 2010
Start
Nov 2010
Primary completionActual
Jan 2013
CompletionActual
Jul 2013
Results first posted
Oct 5, 2016
Last update
Oct 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01227278
Lead sponsor
MedImmune LLC
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Oct 25, 2010
Start date
Nov 2010
Primary completion
Jan 2013
Completion
Jul 2013
Results posted
Oct 5, 2016
Last update
Oct 5, 2016

Study contacts

Rene van der Merwe, MBChB
study director · MedImmune Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion